Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Cusi

Showing results (91-100 of 189) with videos related to

Pageof 19
Sort By:
Metabolism: Clinical and Experimental|June 28, 2023
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United StatesPegah Golabi, James M Paik, Ameeta Kumar, et al.
JMIR Medical Informatics|June 6, 2022
Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk ScoresYonghui Wu, Xi Yang, Heather L Morris, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 11, 2015
Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver diseaseNishanth E Sunny, Srilaxmi Kalavalapalli, Fernando Bril, et al.
Diabetes|September 30, 2003
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetesSangeeta Kashyap, Renata Belfort, Amalia Gastaldelli, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 15, 2002
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjectsThongchai Pratipanawatr, Wilailak Pratipanawatr, Clifford Rosen, et al.
Contemporary Clinical Trials|October 11, 2020
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkersStephen A Harrison, Salvatore Calanna, Kenneth Cusi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without DiabetesFernando Bril, Michael J McPhaul, Srilaxmi Kalavalapalli, et al.
Nature Reviews. Gastroenterology & Hepatology|October 23, 2020
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptorsSven Francque, Gyongyi Szabo, Manal F Abdelmalek, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndromeRachele Berria, Amalia Gastaldelli, Scott Lucidi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2014
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase LevelsPaola Portillo Sanchez, Fernando Bril, Maryann Maximos, et al.
Pageof 19

Showing results (91-100 of 189) with videos related to

Sort By:
Pageof 19
Metabolism: Clinical and Experimental|June 28, 2023
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United StatesPegah Golabi, James M Paik, Ameeta Kumar, et al.
JMIR Medical Informatics|June 6, 2022
Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk ScoresYonghui Wu, Xi Yang, Heather L Morris, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 11, 2015
Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver diseaseNishanth E Sunny, Srilaxmi Kalavalapalli, Fernando Bril, et al.
Diabetes|September 30, 2003
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetesSangeeta Kashyap, Renata Belfort, Amalia Gastaldelli, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 15, 2002
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjectsThongchai Pratipanawatr, Wilailak Pratipanawatr, Clifford Rosen, et al.
Contemporary Clinical Trials|October 11, 2020
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkersStephen A Harrison, Salvatore Calanna, Kenneth Cusi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without DiabetesFernando Bril, Michael J McPhaul, Srilaxmi Kalavalapalli, et al.
Nature Reviews. Gastroenterology & Hepatology|October 23, 2020
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptorsSven Francque, Gyongyi Szabo, Manal F Abdelmalek, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndromeRachele Berria, Amalia Gastaldelli, Scott Lucidi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2014
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase LevelsPaola Portillo Sanchez, Fernando Bril, Maryann Maximos, et al.
Pageof 19